Abbisko Therapeutics has entered into a strategic research collaboration and licence agreement with Eli Lilly and Company to discover and develop innovative medicines across multiple disease targets.

• Collaboration Scope: Abbisko will conduct discovery and early development activities for novel drug programmes directed at disease targets selected by Eli Lilly.
• Partnership: The agreement expands the companies’ existing collaboration and supports the discovery and development of medicines across multiple targets.
• Partnership History: The collaboration builds on a global collaboration and exclusive licence agreement established between Abbisko and Eli Lilly in 2022.

This summary is based on a news report published by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.